

Notice under Section 708A(5)(e) of the Corporations Act

30 October 2023: Orthocell Limited ASX: OCC, “Orthocell” or “the Company”) is pleased to advise that it has today issued 1,714,286 fully paid ordinary shares (“**UWA Shares**”) at a deemed issue price of \$0.35 per UWA Share, pursuant to the agreement with the University of Western Australia (“**UWA**”) announced on 30 October 2023.

The UWA Shares were issued pursuant to the Company’s capacity under ASX Listing Rule 7.1.

The Company gives notice under section 708(5)(e) of the Corporations Act 2001 (Cth) (“**Act**”) that:

- (a) the UWA shares were issued without disclosure to investors under Part 6D.2 of the Act;
- (b) the notice is being given under section 708A(5)(e) of the Act;
- (c) as at the date of this notice the Company has complied with:
 - (i) the provisions of Chapter 2M of the Act, as they apply to the Company; and
 - (ii) sections 674 and 674A of the Act; and
- (d) as at the date of this notice, there is no information that is ‘excluded information’ within the meanings of sections 708(A)(7) and 708A(8) of the Act⁶ that is required to be set out in this notice.

Release authorised by The Board of Directors of the Company.

For more information, please contact:

General & Investor enquiries

Paul Anderson

Orthocell Limited

Managing Director

P: +61 8 9360 2888

E: paul.anderson@orthocell.com.au

Media enquiries

Haley Chartres

HACK Director

P: +61 423 139 163

E: haley@hck.digital

About Orthocell Limited

ACN 118 879 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include CelGro™ platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian market. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company’s other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer, manufacturing scale up and FDA engagement in advance of a randomised controlled study under FDA supervision.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

